AbbVie wows with $30bn blockbuster
AbbVie enjoyed the undivided attention of US bond investors on Tuesday when it hit the market with a $30bn 10 tranche deal that, remarkably for such a big deal, priced with a negative new issue concession.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: